Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Ravina

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Neurology|August 27, 2010
Biomarkers of PD progression: is CSF the answer?Dag Aarsland, Bernard Ravina
Nature Clinical Practice. Neurology|May 5, 2007
Why hasn't neuroprotection worked in Parkinson's disease?Karl Kieburtz, Bernard Ravina
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 2013
Many roads lead to Parkinson's diseaseBernard Ravina, Dag Aarsland
Current Neurology and Neuroscience Reports|July 2, 2008
Neuroprotection in Parkinson's disease: myth or reality?Tiffini Voss, Bernard Ravina
Current Opinion in Neurology|July 19, 2003
Brain banking for neurodegenerative diseasesDiane D Murphy, Bernard Ravina
Seminars in Neurology|March 29, 2007
Neuroprotection in Parkinson's disease: an elusive goalKevin M Biglan, Bernard Ravina
Controlled Clinical Trials|April 12, 2002
Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's diseaseMary E Putt, Bernard Ravina
Neurology|July 10, 2002
Preference-based quality-of-life in patients with Parkinson's diseaseAndrew Siderowf, Bernard Ravina, Henry A Glick
Nature Neuroscience|October 31, 2002
From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsJill Heemskerk, Allan J Tobin, Bernard Ravina
Movement Disorders : Official Journal of the Movement Disorder Society|April 24, 2014
Cognition in movement disorders: where can we hope to be in ten years?David Burn, Daniel Weintraub, Bernard Ravina, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Neurology|August 27, 2010
Biomarkers of PD progression: is CSF the answer?Dag Aarsland, Bernard Ravina
Nature Clinical Practice. Neurology|May 5, 2007
Why hasn't neuroprotection worked in Parkinson's disease?Karl Kieburtz, Bernard Ravina
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 2013
Many roads lead to Parkinson's diseaseBernard Ravina, Dag Aarsland
Current Neurology and Neuroscience Reports|July 2, 2008
Neuroprotection in Parkinson's disease: myth or reality?Tiffini Voss, Bernard Ravina
Current Opinion in Neurology|July 19, 2003
Brain banking for neurodegenerative diseasesDiane D Murphy, Bernard Ravina
Seminars in Neurology|March 29, 2007
Neuroprotection in Parkinson's disease: an elusive goalKevin M Biglan, Bernard Ravina
Controlled Clinical Trials|April 12, 2002
Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's diseaseMary E Putt, Bernard Ravina
Neurology|July 10, 2002
Preference-based quality-of-life in patients with Parkinson's diseaseAndrew Siderowf, Bernard Ravina, Henry A Glick
Nature Neuroscience|October 31, 2002
From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsJill Heemskerk, Allan J Tobin, Bernard Ravina
Movement Disorders : Official Journal of the Movement Disorder Society|April 24, 2014
Cognition in movement disorders: where can we hope to be in ten years?David Burn, Daniel Weintraub, Bernard Ravina, et al.
Pageof 8